Like what you've read?

On Line Opinion is the only Australian site where you get all sides of the story. We don't
charge, but we need your support. Here�s how you can help.

  • Advertise

    We have a monthly audience of 70,000 and advertising packages from $200 a month.

  • Volunteer

    We always need commissioning editors and sub-editors.

  • Contribute

    Got something to say? Submit an essay.

 The National Forum   Donate   Your Account   On Line Opinion   Forum   Blogs   Polling   About   
On Line Opinion logo ON LINE OPINION - Australia's e-journal of social and political debate


On Line Opinion is a not-for-profit publication and relies on the generosity of its sponsors, editors and contributors. If you would like to help, contact us.


RSS 2.0

Innovation needed in mental health treatment

By Andrew Robb and Tania de Jong - posted Tuesday, 30 June 2020

Struggling with your mental health confronts you. Depression, for its part, can overwhelm with false anxieties and meaningless, torturous agitation. It can suck the joy from life and sap your energy. When you're in that black hole, it can seem as though there's no way out.

Before the coronavirus pandemic, one in five Australian adults was already experiencing a chronic mental health condition. One in eight – and one in four older adults – were using antidepressants and, on average, eight Australians took their own lives each day.

These are terrible statistics ­– stark realities that saw Australia experience the highest prevalence of depression in the world, tied with Estonia, according to the World Health Organisation. But even these numbers fail to capture everything: the untold personal and family suffering, the enormous costs to our economy. They will never do justice to the heartache, suffering and community damage.


Now, in the wake of Covid-19, mental health experts are warning the trauma caused by the lockdown, the employment loss and anxiety associated with the pandemic could be far higher than the physical health impacts of the virus itself, with younger people particularly vulnerable.

As Professor Patrick McGorry recently said: "Societies that experience a crisis tend to see a roughly 20 per cent increase in new cases of mental illness. A massive economic downturn will cause society to fracture and even disintegrate. The consequences of an economic collapse will be much more severe and long-lasting".

The fallout from this crisis will have a long tail – one likely to stretch out for months and years after it is lifted. In the absence of affirmative action, many Australians will suffer.

For some, domestic confinement can mean a living hell; for many, it will exacerbate stressors that have long been issues in our lives, and mental health. Policymakers don't always understand that not everyone is lucky enough to have a house with a yard, or a happy relationship. At the same time, the more than two million Australians living in single-person households now face greater isolation and loneliness.

Drawing insights from previous health quarantines, a research review published in The Lancet found that "the psychological impact of quarantine is wide-ranging, substantial, and can be long lasting". None of the quarantines cited were on the scale of our present lockdown. "This is," as Dr Elke Van Hoof, professor of health psychology at Vrije Universiteit Brussel recently described it, "arguably the largest psychological experiment ever conducted."

The key challenge faced by our mental health system in dealing with this crisis is the absence of effective treatments for many Australians – and the absence of scale-able treatment innovation for nearly five decades. Instead, we continue to mostly see variations on the same themes, which help some people but don't aid many others.


In the wake of Covid-19, and the recent bushfire tragedy, the government should move to form a Mental Health Innovation Taskforce – a body that can guide the government in planning new and innovative ways of managing the mental health epidemic triggered by these events.

Such a taskforce would be made up of frontline organisations and key stakeholder groups, such as psychiatrists, general practitioners, psychologists, addiction specialists and other mental health experts, as well as representation from key patient groups.

The development of a government strategy to tackle the burgeoning mental health crisis also needs to include the evaluation and possible introduction of innovative treatment options.

Innovation is needed because remission rates for people experiencing depression, using the standard treatments of antidepressants and psychotherapy, are only about 35 per cent effective. The remission rates for post-traumatic stress disorder are even lower than this – current treatments achieve relief from symptoms for only about 20 per cent of sufferers.

Simply doing more of the same, or making only incremental changes to the current system, is not going to solve this problem and relieve the pain for the millions who are suffering. To create positive change, we have to be innovative and broaden the tools available to our medical practitioners and qualified therapists working in this area.

Our charitable organisation, Mind Medicine Australia, was formed with a view to history. In the 1950s and 1960s, psychedelic-assisted psychotherapy was regarded by psychiatrists as the next big breakthrough for treating key mental illnesses. These medicines were used to successfully treat more than 40,000 patients for a variety of conditions.

In the 70s, though, during Richard Nixon's War on Drugs, they were criminalised for political reasons, to suppress the anti-war movement. The study of psychedelics halted, as did their role in tackling very thorny mental health conditions. Professor David Nutt, head of Neuropsychopharmacology at London's Imperial College, describes this as "the worst censorship of research and medical treatment in the history of humanity".

We have lost half a century. But in recent years the early promise of extraordinary outcomes with psychedelic-assisted therapy has been rekindled by some of the world's leading universities and hospitals including Harvard, Yale, John Hopkins, Imperial College and Oxford, and at St Vincent's Hospital in Melbourne. There are more than 119 current and recently completed trials taking place around the world.

It is important to distinguish between recreational use of these drugs, and medicines being used in a medically controlled environment. Around the world, recognising the medical value of these treatments, many countries are drawing this distinction.

In the US, psychedelic-assisted psychotherapies have been granted "Breakthrough Therapy Designation" by the Food and Drug Administration. MDMA-assisted psychotherapy has been approved for use through Special Access Schemes – similar to those used in Australia for medicinal cannabis – in Israel, the US and Switzerland for patients who are resistant to existing forms of treatment.

These medicines never leave the security of the hospital or clinic, and patients can be properly cared for by experienced clinicians. In this environment, all evidence shows them to be safe and not creating a risk of addiction.

As our fellow MMA board director Dr Simon Longstaff, AO, has said: "We also believe that we should not allow the prejudices of the past to deny relief in the present. If these medicines are safe and effective when applied in a clinical environment, as current research suggests, then Australian governments have an obligation to make them available."

In the US and Europe, phase three medical trials are already under way using MDMA-assisted psychotherapy for PTSD. There are also Phase 2(b) trials underway using psilocybin-assisted psychotherapy for depression. In the US, the approval process for both treatments has been fast-tracked because earlier trials showed lasting impact and high remission rates; and because of the urgent need for new treatments.

Phase 2 trials demonstrated remission rates in 60-80 per cent of patients suffering from depression and post-traumatic stress disorder. Other trials using these therapies for substance abuse are also showing great promise. New trials are also underway for the treatment of eating disorders, OCD and dementia.

These early studies suggest both therapies could be orders of magnitude more effective than antidepressants for the treatment of depression.

Remarkably, these results are being achieved in only two to three sessions, in contrast to conventional treatments, which can require, for many people, daily medications and weekly psychotherapy over decades and lifetimes.

In so many areas of health, Australia leads the world. But we are being left behind when it comes to one of the most promising opportunities in mental health – the use of psychedelic-assisted psychotherapies. This is a chance for Australia to practice the innovation that is so often talked about, to step up and expand our treatment options.

If we are serious about solving our deepening mental health crisis, we need to focus on innovation in treatments as an urgent priority.

  1. Pages:
  2. 1
  3. 2
  4. All

This article was first published in the Saturday Paper.

Discuss in our Forums

See what other readers are saying about this article!

Click here to read & post comments.

28 posts so far.

Share this:
reddit this reddit thisbookmark with Del.icio.usdigg thisseed newsvineSeed NewsvineStumbleUpon StumbleUponsubmit to propellerkwoff it

About the Authors

Andrew Robb AO was Australia's Minister for Trade, Investment and Tourism. He has suffered with depression for 43 years and is a director of Mind Medicine Australia.

Tania de Jong is a social entrepreneur and co-Founder of Mind Medicine Australia, Founder of Creative Innovation Global, Creative , The Song Room and Creativity Australia. and

Other articles by these Authors

All articles by Andrew Robb
All articles by Tania de Jong

Creative Commons LicenseThis work is licensed under a Creative Commons License.

Photo of Andrew RobbAndrew RobbPhoto of Tania de JongTania de Jong
Article Tools
Comment 28 comments
Print Printable version
Subscribe Subscribe
Email Email a friend

About Us Search Discuss Feedback Legals Privacy